Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (July 2019)

20 slides from Aerie Pharmaceuticals's investor presentation, Jul 23, 2019

  1. Slide 1: Company Overview Investor Presentation July 2019

    Slide 1: Company Overview Investor Presentation July 2019

    Company Overview Investor Presentation July 2019 Exhibit 99.1

  2. Slide 2: Disclaimer and forward-looking statements

    Slide 2: Disclaimer and forward-looking statements

    The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference to repor

  3. Slide 3: Aerie Overview

    Slide 3: Aerie Overview

    For Investor Use Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are pre-clinical molecules and hav

  4. Slide 4: Glaucoma Market Perspective

    Slide 4: Glaucoma Market Perspective

    For Investor Use Glaucoma Market Perspective - ~$3B Market, 35M TRx, 52M bottles - Half of volume first-line (PGAs) - Half of volume 2-3X/Day Adjuncts 2018 U.S. Glaucoma Market Graph Source: IQVIA 2018 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Source: IMS/NPA Data R12M May

  5. Slide 5: Rhopressa and Rocklatan Positioning

    Slide 5: Rhopressa and Rocklatan Positioning

    For Investor Use Rhopressa® and Rocklatan® Positioning HCP’s positioning as concomitant therapy HCP’s positioning as therapy for patients requiring maximal IOP lowering with one drop per day Rhopressa® Positioning Rocklatan® Positioning Efficacy vs. other adjunctive therapies QD PM dose Lack of seri

  6. Slide 6: Rocklatan Month 12 Responder Analysis

    Slide 6: Rocklatan Month 12 Responder Analysis

    For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

  7. Slide 7: U.S. Glaucoma Franchise Launch Update

    Slide 7: U.S. Glaucoma Franchise Launch Update

    For Investor Use U.S. Glaucoma Franchise Launch Update Actual Sales-Out to Pharmacies data as of 7/19/19 IQVIA data as of 7/12/19 Actual bottles dispensed exceed Rx’s due to extended supply plans (e.g., 90 days’ supply) Rhopressa® and Rocklatan® have not been approved by any regulatory authority oth

  8. Slide 8: Gaining Market Access

    Slide 8: Gaining Market Access

    For Investor Use Gaining Market Access Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Access as of July 2019: Commercial ~ 90% Medicare Part D ~ 75% Rocklatan® Expected Access by end of September 2019: Commercial ~ 75% (Rhopressa® ~

  9. Slide 9: Launch Considerations

    Slide 9: Launch Considerations

    For Investor Use Launch Considerations Aerie is in the unique position of gaining coverage for Rocklatan® while continuing to grow Rhopressa® Underlying formulary coverage is sometimes delayed Physicians are navigating through the treatment paradigm to optimize patient care while considering patient

  10. Slide 10: Active Engagement at Key Conferences

    Slide 10: Active Engagement at Key Conferences

    For Investor Use Active Engagement at Key Conferences March 2019: American Glaucoma Society (AGS) April/May 2019: Association of Research in Vision and Ophthalmology (ARVO) May 2019: American Society of Cataract and Refractive Surgeons (ASCRS) July 2019: American Society for Retina Specialists (ASRS

  11. Slide 11: Expanding Aerie Franchise: Europe

    Slide 11: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, regulatory decision expected by end of 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® in Europe) for non-inferiority to a fixed

  12. Slide 12: Expanding Aerie Franchise: Japan

    Slide 12: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Advancing clinical development on our own, established branch office in Tokyo Phase 1 completed; successful Pilot Phase 2 completed in the U.S. on Japanese and Japanese-Americans; Phase 2 commenced in Japan, enrollment completed July 2019 Phase 2 Stu

  13. Slide 13: Advancing the Pipeline

    Slide 13: Advancing the Pipeline

    Advancing the Pipeline Drug/Target Indication Development Stage Discovery Preclinical Phase 1/2a AR-1105 Implant (Dexamethasone) RVO AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement AR-xxxxx Implant (ROCK/JAK/IKK) Dry AMD/GA AR-xxxxx (JAK, IKKb) Dry Eye/MGD AR-xxxxx (ROCK, JAK, I

  14. Slide 14: Retinal Eye Diseases – Aerie's Next Chapter

    Slide 14: Retinal Eye Diseases – Aerie's Next Chapter

    For Investor Use Retinal Eye Diseases – Aerie’s Next Chapter Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular

  15. Slide 15: 2018 U.S. Retinal Disease Market

    Slide 15: 2018 U.S. Retinal Disease Market

    For Investor Use 2018 U.S. Retinal Disease Market 2018 Sales: $6.0B 2018 Unit Sales: 7.3MM Sources: Mixture of public information, IQVIA, Market-Scope and estimates – March 2019

  16. Slide 16: Aerie's Innovation in Retinal Disease

    Slide 16: Aerie's Innovation in Retinal Disease

    For Investor Use Aerie’s Innovation in Retinal Disease Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug can

  17. Slide 17: Retinal Eye Disease: Unmet Needs in AMD and DME

    Slide 17: Retinal Eye Disease: Unmet Needs in AMD and DME

    For Investor Use Retinal Eye Disease: Unmet Needs in AMD and DME Need new treatments to address disease mechanisms beyond VEGF Complex pathology cannot be addressed by a single drug class Anti-VEGFs are used to treat the eye with wet AMD, while the second eye typically has dry AMD and a high risk of

  18. Slide 18: Aerie's Lead Retina Product Candidates

    Slide 18: Aerie's Lead Retina Product Candidates

    For Investor Use Aerie’s Lead Retina Product Candidates AR-1105 (Dexamethasone) Implant Indications: retinal vein occlusion (RVO) and DME Target product profile vs. Ozurdex® Longer duration of efficacy (6 mo vs 3 mo) Improved administration due to smaller needle Potential for fewer adverse effects d

  19. Slide 19: AR-13503 Synergistic to Eylea in Mouse Model of PDR

    Slide 19: AR-13503 Synergistic to Eylea in Mouse Model of PDR

    For Investor Use AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR -40% * Administration: Intraperitoneal QD * : p<0.01 *** : p<0.0001 -60% % of Total Area Neovascular Area (+SEM) Data on File Sub-optimal dose level

  20. Slide 20: Summary Key Priorities

    Slide 20: Summary Key Priorities

    For Investor Use Summary Key Priorities Rhopressa®: Continued successful launch execution Rocklatan®: Successful launch execution Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Rhopressa® normal tension glaucoma, p

Source: SEC EDGAR · 8-K filed Jul 23, 2019

More decks from Aerie Pharmaceuticals Inc.